06/19/2026
Could new federal biotechnology legislation reshape how life sciences companies structure partnerships and licensing agreements?
The proposed Biotechnology Innovation and National Security Act (BINSA) could expand government review of certain biotechnology transactions involving covered foreign entities.
For biotech companies, the implications may extend well beyond manufacturing and supply chains—potentially affecting licensing, collaborations, and investment decisions.
Read more: https://ow.ly/wHFN50Zbiub
What questions does your organization have about BINSA?